Daridorexant
16 February 2022
No Comments
We would like to introduce the new column that arrives in our first issue
Archives: Articles
GRIFOLS – Sharing a few words about small-volume parenteral manufacturing with Oriol Argemí, Oriol Prat and Marga Viñes
16 February 2022
No Comments
GRIFOLS IN CDMO MARKET & PARENTERAL TRENDS Grifols is in the CDMO market
European APIs producers: key role in the future scenario of health system
16 February 2022
No Comments
There are many problems in Europe related to the normal distribution and production of essential drugs, due to the shortage of APIs (Active pharmaceutical ingredient) and key intermediates utilized in the synthesis of API. These products are mainly coming from Asia, particularly from China, that, during the last years had to face many problems related to the imposed shutdown of many factories.
The situation is more and more difficult, but there are solutions. With good politics, good industrial actions plans and a careful vision of the future, including not only our needs, but the worldwide needs, we can overcome the current difficulties, and, even more important, to be prepared to other crisis.
Olon – Highly potent products for a more sustainable drug supply chain
16 February 2022
No Comments
“Innovation Initiatives” is a long-term vision that drives Olon’s growth. A strategy of significant
NEWS
16 February 2022
No Comments
INNOVATIVE KITS MINIMISE DOWNTIME FOR GLASS REACTOR VESSEL CHANGEOVER Asynt has introduced two new
Angelini Pharma continues its commitment to HPAPI services
16 February 2022
No Comments
INTRODUCTION The percentage of HPAPI drug candidates in the clinical development is rising
What will Quality Management look like in 2025?
16 February 2022
No Comments
What does the future hold for Quality Management as smart automation offers new ways
Cell and gene therapies: Technology and opportunities
16 February 2022
No Comments
Cell and gene therapies (C>) are a fast growing and promising class of medicines that offer the possibility of curing conditions with a genetic basis that have few or no other therapeutic options for patients. From a turbulent start in the 1990s, with some notable setbacks in clinical trials, the promise of these therapies has now become a reality, with numerous market approvals in recent years, a robust clinical pipeline and strong industry and investor interest. The sector is both immature, from the regulatory and CMC perspectives, and growing fast. Numerous challenges will need to be surmounted in the coming years to ensure that these therapies can reliably reach patients, but the future looks very promising.
Indena’s CDMO services are more and more strategic
16 February 2022
No Comments
The CDMO – Contract Development and Manufacturing Organization area of business of the
Targets and challenges of Pharma Supply Chain Manufacturers
16 February 2022
No Comments
After almost two years of COVID-19 pandemic, we are still in a condition where